de novo study

Description

Sorafenib is a cancer treatment that has been approved for use in human renal cell carcinoma and hepatocellular carcinoma. It has a distinctive inhibitory activity that may be especially valuable at preventing the harmful resistance mechanism known as “evasive resistance” (the promotion of metastasis despite drug activity against the primary tumor). We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

Eligibility criteria

• Any dog with a history of cancer that has a measurable solid tumor
• Dogs that weigh >5kg and <45kg

Participating hospitals

• Massachusetts Veterinary Referral Hospital, Woburn, MA
• Peak Veterinary Referral Center, Williston, VT
• Port City Veterinary Referral Hospital, Portsmouth, NH
• The Oncology Service, Richmond, VA
• The Oncology Service, Springfield, VA
• WVRC – Waukesha, WI

Interested?

Enroll or request more information below